Nasdaq: $28.12 (-1.61) | AIM: £4.12 (-0.04)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Major Shareholders
Financial Reports
SEC Filings
Share Price & Chart
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Careers
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Major Shareholders
Financial Reports
SEC Filings
Share Price & Chart
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
Audit Committee – Terms of Reference
AIM Rule 26
Careers
News & Presentations
Hutchmed
| News & Presentations
Key RNS & Press Releases
20 May 2021
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
Read more
17 May 2021
Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors
Read more
7 May 2021
HUTCHMED to Attend Upcoming Investor Conferences
Read more
4 May 2021
Change of Company Name
Read more
Presentations & Publications
4 Jun 2021
ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
Read more
4 Jun 2021
ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)
Read more
4 Jun 2021
ASCO 2021: A Multicenter Open-Label Phase 1 Study Evaluating the Safety and Tolerability of HMPL-306 in Patients with Locally Advanced or Metastatic Solid Tumors with IDH Mutations
Read more
20 May 2021
Company Update: R&D, Commercial and ASCO Data
Read more
Other UK Regulatory Notices
28 Apr 2021
Results of Annual General Meeting
Read more
23 Apr 2021
Vesting of awards under the Long Term Incentive Plan
Read more
14 Apr 2021
Notification of Dilution of Voting Rights
Read more
29 Mar 2021
Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
Read more
10 Mar 2021
Vesting of awards under the Long Term Incentive Plan
Read more
3 Feb 2021
Chi-Med to Announce 2020 Final Results
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.